166 related articles for article (PubMed ID: 10585160)
21. Transneuronal degeneration in substantia nigra pars reticulata following striatal excitotoxic injury in adult rat: time-course, distribution, and morphology of cell death.
Stefanis L; Burke RE
Neuroscience; 1996 Oct; 74(4):997-1008. PubMed ID: 8895868
[TBL] [Abstract][Full Text] [Related]
22. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization.
Ferrante RJ; Kowall NW; Cipolloni PB; Storey E; Beal MF
Exp Neurol; 1993 Jan; 119(1):46-71. PubMed ID: 8432351
[TBL] [Abstract][Full Text] [Related]
23. Localization of high affinity [3H]glibenclamide binding sites within the substantia nigra zona reticulata of the rat brain.
Hicks GA; Hudson AL; Henderson G
Neuroscience; 1994 Jul; 61(2):285-92. PubMed ID: 7969909
[TBL] [Abstract][Full Text] [Related]
24. Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation.
Lindefors N; Brodin E; Tossman U; Segovia J; Ungerstedt U
Exp Brain Res; 1989; 74(3):527-34. PubMed ID: 2468514
[TBL] [Abstract][Full Text] [Related]
25. Neonatal hypoxic-ischemic or excitotoxic striatal injury results in a decreased adult number of substantia nigra neurons.
Burke RE; Macaya A; DeVivo D; Kenyon N; Janec EM
Neuroscience; 1992 Oct; 50(3):559-69. PubMed ID: 1359461
[TBL] [Abstract][Full Text] [Related]
26. Divergent regulatory mechanisms governing BDNF mRNA expression in cerebral cortex and substantia nigra in response to striatal target ablation.
Rite I; Machado A; Cano J; Venero JL
Exp Neurol; 2005 Mar; 192(1):142-55. PubMed ID: 15698628
[TBL] [Abstract][Full Text] [Related]
27. Localization of striatal and nigral tachykinin receptors in the rat.
Stoessl AJ
Brain Res; 1994 May; 646(1):13-8. PubMed ID: 7519961
[TBL] [Abstract][Full Text] [Related]
28. Topography of substantia nigra innervation by D1 receptor-containing striatal neurons.
Altar CA; Hauser K
Brain Res; 1987 Apr; 410(1):1-11. PubMed ID: 2953407
[TBL] [Abstract][Full Text] [Related]
29. Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions.
Beal MF; Kowall NW; Swartz KJ; Ferrante RJ; Martin JB
Synapse; 1989; 3(1):38-47. PubMed ID: 2563916
[TBL] [Abstract][Full Text] [Related]
30. Neural grafting in a rat model of Huntington's disease: striosomal-like organization of striatal grafts as revealed by acetylcholinesterase histochemistry, immunocytochemistry and receptor autoradiography.
Isacson O; Dawbarn D; Brundin P; Gage FH; Emson PC; Björklund A
Neuroscience; 1987 Aug; 22(2):481-97. PubMed ID: 2823174
[TBL] [Abstract][Full Text] [Related]
31. Effect of brain lesions on [3H]ohmefentanyl binding site densities in the rat striatum and substantia nigra.
Masuo Y; Wang H; Pélaprat D; Chi ZQ; Rostène W
Chem Pharm Bull (Tokyo); 1992 Sep; 40(9):2520-4. PubMed ID: 1332831
[TBL] [Abstract][Full Text] [Related]
32. Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA.
Venero JL; Beck KD; Hefti F
Neuroscience; 1994 Jul; 61(2):257-68. PubMed ID: 7969907
[TBL] [Abstract][Full Text] [Related]
33. Substance P and substance P receptor histochemistry in human neurodegenerative diseases.
Kowall NW; Quigley BJ; Krause JE; Lu F; Kosofsky BE; Ferrante RJ
Regul Pept; 1993 Jul; 46(1-2):174-85. PubMed ID: 7692486
[TBL] [Abstract][Full Text] [Related]
34. Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum.
Ryu JK; Choi HB; McLarnon JG
Neurobiol Dis; 2005 Nov; 20(2):550-61. PubMed ID: 15916899
[TBL] [Abstract][Full Text] [Related]
35. Excitotoxic and metabolic damage to the rodent striatum: role of the P75 neurotrophin receptor and glial progenitors.
Hanbury R; Charles V; Chen EY; Leventhal L; Rosenstein JM; Mufson EJ; Kordower JH
J Comp Neurol; 2002 Mar; 444(4):291-305. PubMed ID: 11891644
[TBL] [Abstract][Full Text] [Related]
36. Sertraline and venlafaxine improves motor performance and neurobehavioral deficit in quinolinic acid induced Huntington's like symptoms in rats: Possible neurotransmitters modulation.
Gill JS; Jamwal S; Kumar P; Deshmukh R
Pharmacol Rep; 2017 Apr; 69(2):306-313. PubMed ID: 28178592
[TBL] [Abstract][Full Text] [Related]
37. Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid.
Miranda AF; Boegman RJ; Beninger RJ; Jhamandas K
Neuroscience; 1997 Jun; 78(4):967-75. PubMed ID: 9174065
[TBL] [Abstract][Full Text] [Related]
38. Acute and chronic changes in kynurenate formation following an intrastriatal quinolinate injection in rats.
Ceresoli-Borroni G; Guidetti P; Schwarcz R
J Neural Transm (Vienna); 1999; 106(3-4):229-42. PubMed ID: 10392532
[TBL] [Abstract][Full Text] [Related]
39. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively.
Alfinito PD; Wang SP; Manzino L; Rijhsinghani S; Zeevalk GD; Sonsalla PK
J Neurosci; 2003 Nov; 23(34):10982-7. PubMed ID: 14645494
[TBL] [Abstract][Full Text] [Related]
40. Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms.
Reid MS; Herrera-Marschitz M; Hökfelt T; Lindefors N; Persson H; Ungerstedt U
Exp Brain Res; 1990; 82(2):293-303. PubMed ID: 1704847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
